Blockchain Registration Transaction Record

ABVC Receives $250K Payment, Vitargus Deal Worth Up to $93.5M

ABVC BioPharma receives $250K payment from ForSeeCon for Vitargus licensing deal worth up to $93.5M. Innovative ophthalmic device could transform retinal surgery.

This development matters because it represents significant progress in ophthalmic medical technology that could transform retinal surgery outcomes for millions of patients worldwide. Vitargus® addresses critical limitations of current silicone oil treatments by eliminating the need for secondary removal surgeries and improving post-operative recovery experiences. The substantial financial commitment from ForSeeCon validates the technology's commercial potential in a rapidly growing market projected to reach $3.6 billion for vitreous substitutes alone. For patients facing retinal detachment and other vitreoretinal conditions, this innovation could mean fewer surgeries, faster recovery times, and reduced complication risks. The establishment of new research facilities in Taiwan further signals the company's commitment to advancing ophthalmic care through cutting-edge technology and AI-enabled analysis.